Centre Hospitalier Universitaire Amiens-Picardie

This study aimed to translate and assess the psychometric properties of a French Fear of Missing Out scale (PPC). The Fear of missing out is defined as a "pervasive apprehension that others might be having rewarding experiences from which one is absent; it is characterized by the desire to remain continually connected to what others are doing". One hundred and thirty-eight participants completed the PPC, a French version of the Internet Addiction Test - Social Media (IAT-RS), a French Smartphone Addiction Scale - Short Version (SAS-SV) and some subscales of the French Revised Symptom Checklist (SCL-90-R) to test the validity of the scale. A principal components analysis revealed an 8-item PPC with a single factor and good internal validity. Correlations with the SAS-SV and the IAT-RS revealed moderate positive correlations confirming the convergent validity of the scale and supporting the use of the scale for further research findings related to the SCL-90-R subscales. Additional analyses allowed us to note that PPC fully mediated the relationship between anxiety and smartphone addiction, as well as between depression and smartphone addiction. It was also revealed that PPC partially mediated the relationship between anxiety and social media addiction and depression and social media addiction. The PPC has good psychometric qualities and opens up the possibility of assessing the fear of missing out in French populations and testing its relationships with various psychological disorders such as addictive behaviors.

Congenital anomalies of the kidney and urinary tract (CAKUT) account for one-third of all congenital malformations detected by ultrasound. With the introduction of chromosomal microarrays, over 50 genes involved in CAKUT have been identified. The main objective of our study was to assess the contribution of chromosomal analysis performed for CAKUT within our fetal diagnosis and treatment center.

We included pregnancies with CAKUT confirmed by ultrasound from January 2013 to December 2020. Once the diagnosis of CAKUT was established, we collected data about proposal for a fetal sampling, type of fetal sampling and results of fetal sampling. When chromosomal aberration was detected, we recorded the type, size, mode of inheritance (de novo or inherited).

We realized 53 amniocentesis (70.7%), 12 chronionic villus sampling (16%) and 10 fetal blood sampling (13.3%). Three fetal sampling were excluded and we finally studied 72 samples. Among all cases, four fetuses (5.5%) showed aneuploidies: one case of trisomy 18, one case of trisomy 20 and two cases of trisomy 21. Six fetuses (8.3%) showed copy number variations. After diagnosis and at the request of couple, 9 medical termination of pregnancy were performed.

Chromosomal analysis carried out in the exploration of congenital renal anomalies make it possible to establish a diagnosis in certain cases, and on the other hand make it possible to modify the outcome of pregnancy or the management of future pregnancies. Faced with new emerging techniques and considering the diagnostic rate of congenital renal malformations, these analysis have their place.

We present the update of the recommendations of the Société française de radiothérapie oncologique on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumours can be treated by exclusive radiation or surgery followed by postoperative radiation in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, they can be treated by chemoradiation or by induction drugs followed by exclusive radiation. For T4 tumour, surgery must be proposed. Different fractionation schedules are possible: for 35 fractions, the curative dose is 70Gy (delivered at 2Gy per fraction) and prophylactic doses are 50 to 56Gy (delivered at 2Gy per fraction in case of sequential radiotherapy or 1.6Gy in case of simultaneous integrated boost radiotherapy; for 33 fractions, the curative dose is 69.96Gy (delivered at 2.12Gy per fraction) and the prophylactic dose is 52.8Gy (delivered at 1.6Gy per fraction in simultaneous integrated boost radiotherapy or 54Gy in 1.64Gy per fraction); for 30 fractions, curative dose is 66Gy (delivered at 2.2Gy per fraction) and prophylactic dose is 54Gy (delivered at 1.8Gy per fraction in simultaneous integrated boost radiotherapy. Doses over 2Gy per fraction can be delivered when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used for locally advanced cancer with dose levels based on pathologic criteria, delivering 60 to 66Gy for R1 resection and 57.6 to 60Gy for complete resection in bed tumour; 50 to 66Gy in lymph nodes areas regarding extracapsular spread. Target volume delineation recommendations were based on guidelines cited in this article.